1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Gan & Lee Pharmaceuticals.
  6. News
  7. Summary
    603087   CNE100003ZH1

GAN & LEE PHARMACEUTICALS.

(603087)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

07/02/2021 | 03:00am EDT

Gan & Lee Pharmaceuticals Co. Ltd. announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th – 29th. The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany). All three phase 1 studies met their primary PK and primary PD analyses. These data demonstrate pharmacokinetic and pharmacodynamic bioequivalence between each of the proposed biosimilar Gan & Lee insulins and their respective reference compounds. In addition, the safety profiles were comparable between each of the three proposed biosimilar Gan & Lee insulins and their respective reference compounds.


© S&P Capital IQ 2021
All news about GAN & LEE PHARMACEUTICALS.
04/27Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 3..
CI
03/10Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug,..
AQ
03/10Gan & Lee Pharmaceuticals. Begins First-In-Human Trial in U.S. for Investigational Drug..
CI
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New..
CI
2021China’s Drug Procurement Program Cuts Insulin Costs by Around 48%
MT
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September..
CI
2021GAN & LEE PHARMACEUTICALS : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GL..
AQ
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021GAN & LEE PHARMACEUTICALS : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Asp..
AQ
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results a..
CI
More news
Financials
Sales 2022 4 002 M 594 M 594 M
Net income 2022 1 533 M 227 M 227 M
Net Debt 2022 - - -
P/E ratio 2022 15,1x
Yield 2022 -
Capitalization 23 203 M 3 443 M 3 443 M
Capi. / Sales 2022 5,80x
Capi. / Sales 2023 4,79x
Nbr of Employees 3 278
Free-Float -
Chart GAN & LEE PHARMACEUTICALS.
Duration : Period :
Gan & Lee Pharmaceuticals. Technical Analysis Chart | 603087 | CNE100003ZH1 | MarketScreener
Technical analysis trends GAN & LEE PHARMACEUTICALS.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 41,32
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Zhong Ru Gan Chairman
Yan Sun Independent Director
Yan Qing He Independent Director
Guo Jun Zheng Independent Director
Kai Du Director & Director-International Department
Sector and Competitors
1st jan.Capi. (M$)
GAN & LEE PHARMACEUTICALS.-41.26%3 440
CSL LIMITED-5.89%93 252
SAMSUNG BIOLOGICS CO.,LTD.-6.98%46 658
BIOGEN INC.-15.66%29 636
WUXI BIOLOGICS (CAYMAN) INC.-42.41%28 644
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-30.66%21 435